Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lu ag09222
- Development stage
- Phase 2
- Lead developer
- Lundbeck
- Modality
- IgG Antibodies → Naked Antibodies → Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Subcutaneous, Intravenous
01
Overview
Lu AG09222 is an investigational humanized monoclonal antibody developed for the prevention of migraine. It targets and binds with high affinity to pituitary adenylate cyclase-activating polypeptide (PACAP), a neuropeptide implicated in migraine pathophysiology, thereby inhibiting PACAP from activating its receptors and preventing PACAP-induced arterial dilation. This mechanism is distinct from calcitonin gene-related peptide (CGRP) inhibitors currently used in migraine therapy. Lu AG09222 has shown efficacy in reducing monthly migraine days in clinical trials and is being evaluated as a potential first-in-class therapy for patients who have not responded to other preventive treatments. The drug was originally developed by Alder Biopharmaceuticals and is now being advanced by Lundbeck[2][4][5][7].
- Other names
- anti-pacap-38-antibodyanti-pacap38-antibodyanti-pacap 38-antibodypacap - lundbeck
02
Targets
PACAP (Pituitary adenylate cyclase-activating polypeptide)
Beyond the preview
Go deeper on lu ag09222.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lu ag09222.